075586725195  |  Set Home  |  Favorite  |  中文
Clinical trials
Clinical trials
SearchResults trial GIMI
Date: 2019-12-18


Title

Conditions

Interventions

Locations

1

Intervention of CAR-T Against Cervical Cancer

• Cervical Cancer

• Biological: Cervical cancer-specific CAR-T cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

2

Safety and Efficacy Evaluation of 4th Generation Safety- engineered CAR T Cells Targeting Sarcomas

• Sarcoma
• Osteoid Sarcoma
• Ewing Sarcoma

• Biological: Sarcoma-specific CAR-T cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

3

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

• Lung Cancer
• NSCLC

• Biological: LC-CTLs

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

4

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

• Human Papilloma Virus

• Biological: HPV-CTLs

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

5

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

• Beta-Thalassemia

• Genetic: Gene-modified autologous stem cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

6

Lentiviral FVIII Gene Therapy

• Hemophilia A

• Biological: YUVA-GT-F801

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

7

Genetically Modified T Cells Against Ovarian Cancer

• Ovarian Cancer

• Biological: OC-IgT cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

8

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

• Pathogen Infection
• EBV Infection
• CMV Infection
• Adenovirus Infection
• BKV Infection
• Fungus Infection
• Tuberculosis

• Biological: pathogen-specific CTLs

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

9

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

• Solid Tumor

• Genetic: 4SCAR-GD2

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

10

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

• Glioblastoma Multiforme of Brain
• Glioblastoma Multiforme

• Biological: Antigen-specific IgT cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China

11

Intervention of Bladder Cancer by CAR-T

• Bladder Cancer
• Urothelial Carcinoma Bladder

• Genetic: 4SCAR-PSMA
• Genetic: 4SCAR-FRa

• Shenzhen Second People Hospital, Shenzhen, Gongdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

12

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

• Multiple Myeloma

• Biological: CAR T cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• The First People's Hospital of Yunnan, Kunming, Yunnan, China

13

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

• B-cell Malignancies

• Genetic: Therapeutic 4SCAR19 cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• The First People's Hospital of Yunnan, Kunming, Yunnan, China

14

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

• Acute Myeloid Leukemia

• Biological: Muc1/CLL1/CD33/CD38/CD56/ CD123-specific gene-engineered T cells

• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, KunMing, Yunnan, China

15

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

• B-cell Malignancies

• Biological: 4SCAR19 and 4SCAR22
• Biological: 4SCAR19 and 4SCAR38
• Biological: 4SCAR19 and 4SCAR20
• Biological: 4SCAR19 and 4SCAR123
• Biological: 4SCAR19 and 4SCAR70
• Biological: 4SCAR19 and 4SCAR30

• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

16

FANCA Gene Transfer for Fanconi Anemia Using a High- safety, High-efficiency, Self-inactivating Lentiviral Vector

• Fanconi Anemia

• Genetic: Gene-modified autologous stem cells

• Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China
• Beijing Children's Hospital, Beijing, Beijing, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

17

Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector #TYF-IL-2Rg#

• SCID, X Linked

• Biological: TYF-IL-2Rg gene-modified autologous stem cells

• Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China
• Beijing Children's Hospital, Beijing, Beijing, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

18

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

• Ovarian Cancer

• Biological: OC-EIEs

• Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

19

Engineered Immune Effectors Against Cervical Cancer

• Cervical Cancer

• Biological: CC-EIEs

• Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

20

Engineered Immune Effectors Against Ovarian Cancer

• Ovarian Cancer

• Biological: OC-CTLs

• Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

21

Antigen-specific T Cells Against Lung Cancer

• Lung Cancer

• Biological: Lung cancer-specific T cells

• Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

22

Multiple CAR-T Cell Therapy Targeting AML

• Acute Myeloid Leukemia

• Biological: CLL-1, CD33 and/or CD123- specific CAR gene-engineered T cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

23

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

• Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

• Genetic: TYF-ADA gene-modified autologous stem cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

24

Immunotherapy Treating GI Cancer

• Cancer

• Biological: engineered immune cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

25

Immune Modulatory DC Vaccine Against Brain Tumor

• Diffuse Intrinsic Pontine Glioma or Glioblastoma

• Biological: Immunomodulatory DC vaccine to target DIPG and GBM

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China

26

CAR-T Immunotherapy Targeting CD19- ALL

• B-cell Leukemia

• Biological: 4SCAR-CD22/CD123/CD38/ CD10/CD20/TSLPR

• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Zhongxi Children Hospital, Shijiazhuang, Hebei, China

27

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

• Cancer

• Biological: Engineered Immune Cells

• QiFu Hospital of Guangzhou University of Chinese Medicine, GuangZhou, Guangdong, China
• Shenzhen Geno-immune Medical Institute, ShenZhen, Guangdong, China
• Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, KunMing, Yunnan, China

28

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

• Immune Related Disorder
• Tissue Damage

• Biological: clonal fetal MSCs

• Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Aerospace Center Hospital, Beijing, China

29

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma
• Acute Myeloid Leukemia
• NK Cell Lymphoma

• Biological: CD7-specific CAR gene- engineered T cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

30

Lentiviral Gene Therapy for X-ALD

• X-linked Adrenoleukodystrophy

• Genetic: Intracerebral LV gene therapy

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

31

Lentiviral Gene Therapy for CGD

• Chronic Granulomatous Disease

• Genetic: Infusion of lentiviral TYF-CGD- modified autologous stem cells

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

32

Lentiviral Gene Therapy for MLD

• Metachromatic Leukodystrophy (MLD)

• Biological: Lentivirus-mediated delivery of ARSA to the CNS.

• Lung-Ji Chang, Shenzhen, Guangdong, China

33

Lentiviral FIX Gene Therapy

• Hemophilia B

• Biological: YUVA-GT-F901


34

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

• B-Cell Leukemia
• B-Cell Lymphoma

• Biological: 4SCAR19/22 T cells
• Drug: Interleukin-2

• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

35

A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia

• B Acute Lymphoblastic Leukemia

• Genetic: prophylactic 4SCAR19 cells

• First people's hospital of Yunnan province, Kunming, Yunnan, China

36

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

• Leukemia, Acute Lymphocytic (ALL)
• Leukemia, Acute Myelogenous (AML)
• Myelodysplastic Syndromes

• Biological: Chimeric antigen receptor T cells
• Biological: peptide specific dendritic cell

• Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

37

Immunotherapy Targeting Neurofibromatosis Type II or Schwannomatosis

•Cancer

•Biological/Vaccine: Antigen-specific T cells CART/CTL and DCvac

• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services 


ADD: 深圳市南山区粤兴二道6号虚拟大学园重点实验室平台二层   TEL: 075586725195   Email: gimi_trials@szgimi.org

Copyright © 2016 Shenzhen Genoimmune Medical Institute all rights reserved.